MNG655
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- KRAS_SIGNALING_DN+0.331
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.298
- APICAL_SURFACE+0.274
- MYOGENESIS+0.245
- COAGULATION+0.216
- APICAL_JUNCTION+0.209
- ALLOGRAFT_REJECTION+0.128
- WNT_BETA_CATENIN_SIGNALING+0.116
- INFLAMMATORY_RESPONSE+0.081
- INTERFERON_GAMMA_RESPONSE+0.061
Top 10 suppressed
- MYC_TARGETS_V1-0.595
- OXIDATIVE_PHOSPHORYLATION-0.553
- PROTEIN_SECRETION-0.540
- G2M_CHECKPOINT-0.530
- E2F_TARGETS-0.519
- MTORC1_SIGNALING-0.500
- MYC_TARGETS_V2-0.490
- ANDROGEN_RESPONSE-0.407
- UNFOLDED_PROTEIN_RESPONSE-0.384
- PI3K_AKT_MTOR_SIGNALING-0.332
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
2 twins match this tumor's tissue · 8 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 20040065.TNBC | — | D | 0.903 |
| 2 | SRR1394713 | GTEX | — | 0.903 |
| 3 | BS_MQCKXD60 | Glial-neuronal tumor NOS | — | 0.901 |
| 4 | SRR1378155 | GTEX | — | 0.899 |
| 5 | TCGA-75-7025-01A-12R-1949-07 | — | cohortA1 | 0.897 |
| 6 | SJEPD031_D.RNA-Seq | EPN | Posterior Fossa EPN | 0.896 |
| 7 | SRR1390582 | GTEX | — | 0.892 |
| 8 | SRR1487825 | GTEX | — | 0.891 |
| 9 | BS_21RE8W46 | pilocytic astrocytoma | — | 0.891 |
| 10 | SRR1419714 | GTEX | — | 0.890 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 16 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| KRAS_SIGNALING_DN | 0.331 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.298 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.274 | Temsirolimus | — uncovered |
| MYOGENESIS | 0.245 | Inavolisib | — uncovered |
| COAGULATION | 0.216 | Binimetinib | — uncovered |
| APICAL_JUNCTION | 0.209 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.128 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.116 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.081 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.061 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.039 | Cobimetinib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.023 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.022 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.018 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.018 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.012 | Inavolisib | — uncovered |